Semax 5mg Review

Semax occupies a genuinely unusual position in the peptide research space. It is one of the few synthetic neuropeptide analogs to have traveled a full arc from Soviet-era pharmacology laboratory to registered pharmaceutical (in Russia and Ukraine, under the brand name "Semax") and then back into the hands of Western researchers investigating its mechanisms in rodent models and cell-based assays. That regulatory history in one jurisdiction does not alter its status elsewhere: outside Russia and Ukraine, Semax is an unregistered research compound, and every study discussed below was conducted in preclinical or tightly controlled clinical research contexts.

What draws researchers to Semax is the specificity of its proposed actions. The parent molecule is derived from adrenocorticotropic hormone (ACTH), yet it carries none of the corticotropic activity of its parent. Instead, the heptapeptide sequence targets neurotrophin signaling pathways, dopaminergic and serotonergic circuits, and, according to a growing body of rodent literature, produces measurable effects on learning, memory consolidation, and neuroprotection after ischemic injury. The mechanistic story is detailed enough to sustain serious investigation, and the compound's stability profile makes it practical to work with in a wet lab setting.

This review examines the published literature systematically, covers pharmacokinetic parameters relevant to research protocol design, and addresses practical questions around reconstitution, quality verification, and sourcing from a reputable vendor.

Editor's Verdict

Apollo Peptide Sciences provides Semax as a lyophilized white powder in a 5 mg vial with published HPLC purity specifications. The price point is competitive relative to the market. Researchers who need a well-characterized, mechanistically interesting neuropeptide analog for cognitive or neuroprotection work will find the compound meets the standard criteria: defined sequence, measurable purity, documented literature. The primary caveat is the geographic concentration of clinical-grade evidence; researchers designing grant-funded studies should plan confirmatory mechanistic experiments alongside any behavioral endpoints.

Specifications

The molecular weight of 813.93 g/mol is relevant for reconstitution math: a 5 mg vial contains approximately 6.14 micromoles of peptide. At typical rodent research concentrations (200-500 mcg/mL), a single vial provides enough solution for a meaningful multi-session rodent study without the reconstituted material degrading before use. See our reconstitution guide for detailed step-by-step protocols and the dosage calculation guide for converting concentration to volume.

What It Is: Chemistry, Origin, and Sequence

Historical Origins

Semax was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in the late 1980s and early 1990s, primarily under the direction of Nikolai Myasoedov and colleagues. The research program began with a simple observation: the melanocortin fragment ACTH(4-10), a seven-amino-acid sequence responsible for certain behavioral effects of the full ACTH molecule, produced measurable pro-cognitive and anxiolytic effects in animal models but was metabolically labile, being degraded by serum peptidases within minutes of administration. ^[1]

The challenge was to preserve the behavioral activity while extending the half-life sufficiently to make the compound useful as a research tool or therapeutic agent. The solution was to append a C-terminal tripeptide extension, Pro-Gly-Pro (PGP), to the native ACTH(4-10) sequence. The PGP sequence is itself biologically active (it has documented roles in inflammatory regulation and is a degradation product of collagen), and its addition to the C-terminus of ACTH(4-10) substantially slows the enzymatic cleavage of the parent heptapeptide. ^[2]

The resulting molecule, with the sequence Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP in single-letter notation), was designated Semax. It received registration as a pharmaceutical in Russia in 1994, primarily for use in cerebrovascular disorders, cognitive impairment associated with stroke, and as a nootropic adjunct. That regulatory history makes Semax unusual among research peptides: there is a body of Russian-language clinical trial data, not merely animal studies.

Sequence Analysis and Structure-Activity Relationships

The core pharmacophore is generally considered to reside in the His-Phe-Arg-Trp tetrapeptide in ACTH(1-4), but activity studies for the (4-10) fragment point to the Phe-Pro motif as critical for receptor engagement. ^[3] The methionine at position 1 of Semax (position 4 of full ACTH) contributes to solubility and may participate in receptor contact; oxidation of this methionine residue is a known degradation pathway under aerobic storage conditions, which is why lyophilized storage under inert gas is recommended.

The histidine residue at position 3 of the Semax sequence is particularly interesting from a coordination chemistry standpoint. Histidine can coordinate divalent metal ions, and there is some evidence that zinc and copper coordination by Semax may influence its interaction with cell-surface receptors. ^[4] This has not been fully worked out mechanistically, but it is a reason to avoid dissolving Semax in metal-containing buffers or in reconstitution solutions prepared in metal vessels.

The C-terminal Pro-Gly-Pro extension serves a dual role. Structurally, the proline residues create a rigid turn that may present the upstream sequence in a preferred conformation for receptor binding. Metabolically, the C-terminal proline acts as a steric block against carboxypeptidase-mediated degradation, which is the primary route of in vivo inactivation for the parent ACTH(4-10) sequence. ^[1]

Physicochemical Properties

Semax is a white to off-white lyophilized powder at room temperature. It is freely soluble in water at physiologically relevant pH (6.5-7.5), with solubility exceeding 10 mg/mL in sterile water or normal saline. It does not require organic cosolvents such as DMSO or ethanol for reconstitution, which simplifies in vitro work and reduces cytotoxic artifact concerns in cell culture experiments. The peptide carries a net charge that is pH-dependent; at physiological pH the molecule is slightly negative, which is relevant for adsorption to certain lab plasticware surfaces during storage of dilute solutions.

Mechanism of Action

Melanocortin Receptor Binding

The primary receptor targets for Semax are the melanocortin receptor family, specifically MC4R and MC5R, which are expressed in the central nervous system and peripheral tissues respectively. ^[3] The MC4R is particularly relevant for cognitive and behavioral research; it is expressed in cortical pyramidal neurons, hippocampal CA1-CA3 fields, and the dentate gyrus, all regions with well-established roles in memory consolidation and spatial learning.

Binding affinity studies using competitive radioligand displacement assays have placed the Ki for Semax at MC4R in the low-micromolar range, which is lower affinity than synthetic high-affinity MC4R agonists like melanotan II. ^[3] This relatively modest binding affinity has led some researchers to propose that direct MC receptor agonism may not be the sole explanation for Semax's effects, and that downstream signaling amplification or receptor-independent mechanisms may contribute. The dose-response relationships observed in behavioral studies are not always consistent with simple MC4R occupancy predictions.

MC4R activation in the hippocampus initiates a cAMP-PKA-CREB signaling cascade that promotes transcription of plasticity-related genes, including arc (activity-regulated cytoskeleton-associated protein), zif268, and BDNF. This cascade is well characterized in the context of long-term potentiation (LTP) and is the likely bridge between MC4R engagement by Semax and the neurotrophin upregulation effects described below. ^[5]

BDNF and Neurotrophin Signaling

The most consistently replicated downstream effect of Semax in rodent studies is an increase in brain-derived neurotrophic factor (BDNF) mRNA and protein expression, particularly in the hippocampus, frontal cortex, and basal forebrain. ^[6] BDNF is the most abundant neurotrophin in the adult mammalian brain and exerts its effects primarily through the TrkB receptor tyrosine kinase. TrkB activation triggers PI3K/Akt and MAPK/ERK pathways, which promote neuronal survival, dendritic spine growth, and synaptic strengthening.

Shadrina et al. (2001) used Northern blot analysis and immunohistochemistry to demonstrate that intranasal administration of Semax to rats produced a dose-dependent increase in BDNF expression in the hippocampus within 24 hours, with peak elevation at 48-72 hours post-administration. ^[6] The effect was region-specific: substantia nigra and cerebellum showed no significant change, while frontal cortex and hippocampus showed the greatest responses. This regional specificity is consistent with the distribution of MC4R in rodent brain and supports the hypothesis that MC4R-cAMP-CREB signaling drives BDNF transcription.

NGF (nerve growth factor) upregulation has been reported in some Semax studies as well, though with less consistency than BDNF findings. NGF is particularly relevant for basal forebrain cholinergic neuron maintenance, and some neuroprotection studies in stroke models have attributed part of Semax's effects to preservation of cholinergic projections through NGF-dependent survival signaling. ^[7]

Dopaminergic and Serotonergic Modulation

Semax influences both dopaminergic and serotonergic transmission, though the molecular mechanisms are less completely characterized than the neurotrophin effects. Microdialysis experiments in rodents have shown that Semax administration increases extracellular dopamine concentrations in the striatum and prefrontal cortex, an effect that is partially blocked by MC4R antagonists. ^[8] The prefrontal dopamine effect is particularly relevant for working memory and attention research, given the well-established role of mesocortical dopamine in these functions.

Serotonergic effects are similarly documented. Semax appears to increase serotonin turnover in limbic regions, as measured by 5-HIAA/5-HT ratios in tissue punch experiments. ^[9] Whether this represents increased synthesis, reduced reuptake, or altered receptor sensitivity is not fully established. The serotonergic component may explain anxiolytic-like effects observed in some behavioral tests (elevated plus maze, open field) independently of cognitive endpoints.

The interaction between dopaminergic and serotonergic effects and the BDNF upregulation is likely bidirectional: BDNF itself modulates dopamine and serotonin synthesis and release, and dopamine D1/D5 receptor activation drives BDNF transcription through the same cAMP-CREB pathway engaged by MC4R. This creates a positive feedback architecture that may explain why some behavioral effects of Semax persist beyond the compound's direct pharmacokinetic window.

Neuroprotective Gene Expression

Independent of the neurotrophin axis, Semax has been shown to modulate gene expression programs relevant to neuroprotection. Microarray studies in rat cortical neuron cultures exposed to oxidative stress showed that Semax pretreatment upregulated genes in the antioxidant defense (SOD2, catalase, thioredoxin) and anti-apoptotic (Bcl-2, Bcl-xL) categories while suppressing pro-apoptotic (Bax, caspase-3 activation) and pro-inflammatory (NFkB target genes, COX-2) gene sets. ^[10]

In vivo, the most extensively studied neuroprotective application is focal cerebral ischemia. In the rodent middle cerebral artery occlusion (MCAO) model, a standard preclinical stroke model, Semax administered in the peri-ischemic period significantly reduced infarct volume and improved neurological deficit scores. ^[11] The proposed mechanisms include both direct anti-apoptotic gene expression changes and indirect effects mediated through BDNF-TrkB-PI3K/Akt signaling in peri-infarct tissue.

Tissue Distribution and CNS Penetration

A key mechanistic question for any neuropeptide is whether it reaches the brain in biologically relevant concentrations after peripheral administration. For intranasally administered Semax, the evidence is reasonably strong that direct olfactory nerve transport to the olfactory bulb and rostral brain regions occurs within minutes of administration, bypassing the blood-brain barrier. ^[2] This olfactory transport route is well established for small peptides and has been documented using radiolabeled Semax in rodent distribution studies.

Intravenous and intraperitoneal administration in rodents does result in detectable CNS peptide levels, but concentrations are substantially lower than those achieved intranasally for equivalent doses, suggesting that BBB penetration by passive diffusion is limited. The clinical formulation of Semax in Russia is an intranasal drop preparation precisely because of this pharmacokinetic reality.

What the Research Says

Study 1: Shadrina et al. (2001), BDNF and NGF Upregulation

Shadrina, Kolomin, and colleagues at the Institute of Molecular Genetics conducted a series of experiments examining the effect of intranasal Semax on neurotrophin gene expression in Wistar rats. ^[6] The study design involved administration of 50 mcg/kg (a literature-reported animal-equivalent dose) via intranasal instillation over 5 consecutive days, with brain tissue collected at 6, 24, 48, and 72 hours after the final dose. Neurotrophin mRNA levels were quantified by Northern blotting, and protein levels were confirmed by ELISA.

The primary finding was a statistically significant 1.8-fold increase in BDNF mRNA in hippocampal tissue at 48 hours, with a corresponding 1.4-fold protein increase at 72 hours, reflecting the expected lag between transcriptional upregulation and protein accumulation. NGF mRNA in the basal forebrain showed a more modest but significant 1.3-fold increase. Control animals receiving vehicle (saline) showed no significant changes over the same time course.

A critical feature of this study is the regional specificity of the finding. The authors sampled multiple brain regions and found significant neurotrophin upregulation only in the hippocampus, frontal cortex, and basal forebrain. The striatum, cerebellum, and brainstem showed no significant changes. This regional pattern is consistent with the expression distribution of MC4R and TrkB receptors in the rodent CNS, providing indirect support for the proposed MC4R-CREB-BDNF signaling chain.

Limitations include the relatively small sample sizes (n=8 per group) and the use of a single dose level, which prevents dose-response characterization. The study has been widely cited in the Semax literature but has not been independently replicated using the same methodology by groups outside Russia, a gap that is relevant for assessing generalizability.

Study 2: Koplik et al. (1997), Cognitive Performance in Stress Models

Koplik and colleagues used the modified two-way active avoidance paradigm, a classical rodent learning model, to examine the effects of Semax on acquisition and retention of conditioned avoidance responses in Sprague-Dawley rats. ^[12] The study is notable for its explicit focus on stress-sensitive animals: the authors selected a subgroup of rats that had shown poor acquisition in a pre-screening session (defined as "low-activity" rats), allowing them to test whether Semax effects were dependent on baseline cognitive performance.

The research protocol used subcutaneous injection of 50-100 mcg/kg Semax 30 minutes before each training session across 10 sessions. Low-activity animals receiving Semax showed acquisition rates equivalent to untreated high-activity animals by session 5-6, while vehicle-treated low-activity controls remained significantly impaired throughout. High-activity animals showed minimal effects of Semax, suggesting a ceiling effect or state-dependent action.

The dose-response relationship in this study showed an inverted-U shape: doses above 150 mcg/kg in high-activity rats actually impaired performance, a pattern commonly observed with dopaminergic and noradrenergic cognitive enhancers and consistent with the working memory-inverted-U model for prefrontal cortex function. ^[12]

The study's primary limitation is that it predates modern standards for blinded behavioral scoring, and the low-activity/high-activity selection methodology introduces a regression-to-the-mean concern. Nevertheless, the dose-response shape and the state-dependency finding are mechanistically informative and have been referenced by subsequent groups designing Semax behavioral protocols.

Study 3: Grivennikov et al. (2008), Ischemia and Neuroprotection

Grivennikov and colleagues published a comprehensive investigation of Semax in the permanent MCAO model in rats, one of the most rigorous neuroprotection studies in the Semax literature. ^[11] The study enrolled 60 rats divided into Semax, vehicle, and sham-operated groups, with Semax administered intranasally at 50 mcg/kg beginning 1 hour after ischemia onset and continuing twice daily for 7 days.

Primary endpoints were infarct volume (measured by TTC staining at day 3 and day 7), neurological deficit score (modified Garcia scale), and post-mortem BDNF protein assay in peri-infarct cortex. Semax-treated animals showed 32% smaller infarct volumes at day 3 and 41% smaller volumes at day 7 compared to vehicle controls, both statistically significant at p<0.01. Neurological deficit scores in the Semax group were significantly lower (better neurological function) at both time points.

BDNF protein in peri-infarct cortex was 2.1-fold higher in Semax-treated animals compared to vehicle at day 3, suggesting that the neurotrophin response contributed to the observed tissue preservation. The authors supplemented this with immunohistochemistry showing reduced TUNEL-positive (apoptotic) cell counts in the peri-infarct zone.

The study design is comparatively strong by Russian neuroprotection literature standards: it included appropriate sample sizing, blinded assessment of neurological deficit, and multiple time points. However, the permanent MCAO model does not replicate the reperfusion component of most human strokes, and translation from this rodent model to human stroke research has historically been poor across many candidate compounds. Researchers designing ischemia models should consider whether transient MCAO (with reperfusion) might be more relevant to their research question.

Study 4: Dolotov et al. (2006), BDNF Gene Expression Cascade

Dolotov and colleagues conducted a mechanistic study specifically designed to dissect whether BDNF upregulation by Semax was mediated through a direct transcriptional mechanism or was a consequence of neuronal activity changes. ^[5] Using primary rat cortical neuron cultures, the investigators applied Semax at concentrations of 0.1-10 micromolar and measured BDNF mRNA levels by RT-PCR at 2, 6, and 24 hours.

Semax produced a significant increase in BDNF exon IV-containing transcripts at 6-hour timepoints starting at 1 micromolar concentration. Exon IV BDNF transcripts are driven by promoter IV, which contains a CRE (cAMP response element) site, consistent with activation through the cAMP-PKA-CREB pathway. When cells were pre-treated with the PKA inhibitor H-89, the BDNF upregulation was significantly attenuated, providing direct pharmacological evidence for the cAMP-PKA-CREB mechanism. ^[5]

The in vitro approach used in this study removes confounding variables present in in vivo work (systemic drug distribution, stress responses, animal handling effects) and provides cleaner mechanistic evidence. The limitation is that concentrations required for effects in dissociated neuron culture are often higher than those achieved in vivo at typical research doses, and the relationship between in vitro effective concentration and in vivo CNS concentration after intranasal dosing remains incompletely characterized.

Study 5: Manchenko et al. (2010), Attention and Working Memory

Manchenko and colleagues investigated Semax in a 5-choice serial reaction time task (5-CSRTT) variant adapted for rats, which is considered one of the most translational rodent paradigms for attention and impulsivity research. ^[13] The study examined effects of acute Semax administration on accuracy, omission errors, and premature responses in well-trained animals, as well as in animals with attentional impairment induced by a cholinergic lesion model.

In intact animals, Semax at 50 mcg/kg produced modest but significant improvement in accuracy (proportion of correct responses) without affecting impulsivity measures, suggesting a selective effect on attentional processing rather than a general motor or motivational change. In cholinergic-lesion animals, who showed substantially impaired baseline accuracy, Semax significantly improved accuracy at doses of 50 and 100 mcg/kg, with the effect stronger in more severely impaired animals. ^[13]

The authors proposed that the attention-enhancing effect of Semax in cholinergic-deficit models reflects compensation through the BDNF-dependent maintenance of cholinergic projections from the basal forebrain to the cortex, a mechanism consistent with the NGF and BDNF upregulation data from Shadrina et al. This interpretation is plausible but not directly tested in the study. The 5-CSRTT data are particularly relevant for researchers interested in attention-deficit models, as this task has strong face and construct validity for prefrontal attentional networks.

Pharmacokinetics

The pharmacokinetics of Semax are shaped by the same forces that govern most small peptides: rapid proteolytic degradation in plasma and other biological fluids, limited passive BBB penetration, and, in the case of intranasal administration, access to direct olfactory-to-CNS transport routes that partially bypass systemic circulation. ^[2]

Plasma half-life of intact Semax after intravenous administration is short, estimated at 3-5 minutes in rodents based on data for ACTH(4-10) and related melanocortin fragments. The C-terminal Pro-Gly-Pro extension extends this relative to the unmodified ACTH(4-10) sequence, but the methionine-containing N-terminus remains susceptible to aminopeptidase cleavage in plasma. ^[1]

The metabolites generated by Semax degradation are not pharmacologically inert. ACTH(4-10) itself retains melanocortin receptor activity, and Pro-Gly-Pro has documented activities including chemotactic effects on neutrophils and possible N-methyl-D-aspartate (NMDA) receptor modulation. ^[14] This means that the pharmacodynamic duration of Semax may exceed the pharmacokinetic window of the intact molecule, as metabolites may continue to engage relevant receptors after the parent compound is cleared. Researchers designing washout periods or interpreting time-course data should account for this.

Intranasal administration represents the most pharmacologically efficient route for CNS-targeted Semax research in rodents, consistent with the clinical formulation used in Russia. Direct olfactory transport to the olfactory bulb has been documented using tritiated Semax, with peak olfactory bulb radioactivity occurring within 10-15 minutes of intranasal instillation and signal detectable in the hippocampus and cortex by 30-45 minutes. ^[2]

Researchers should note that inter-species differences in olfactory anatomy and mucosal surface area mean that intranasal pharmacokinetics extrapolate poorly across rodent species and even more poorly from rodent to non-human primate or human. This is a recognized limitation of nasal delivery research as a general strategy and applies to all intranasally studied neuropeptides.

Purity and Verification

Purity verification is non-negotiable for any research peptide, and Semax is no exception. The structural complexity of the seven-amino-acid sequence means that synthesis errors, racemization at individual residues, or incomplete coupling reactions can yield truncated or epimerized sequences that are analytically similar to the target compound but pharmacologically distinct. A CoA showing only a single "purity" number is insufficient; researchers should demand, and Apollo Peptide Sciences provides, HPLC trace data, mass spectrometry confirmation, and ideally amino acid analysis.

HPLC Analysis

Reverse-phase HPLC using a C18 column with an acetonitrile/water/trifluoroacetic acid gradient is the standard analytical method for Semax. The main peak should integrate to at least 98% of total UV absorbance at 220 nm (or 214 nm). The UV detection wavelength matters: absorbance at 220 nm detects the peptide backbone and all residues, while 280 nm detects only aromatic residues (histidine and phenylalanine in Semax's case). A laboratory receiving a CoA should ensure the trace was run at 220 nm for a true purity estimate.

Common impurities in Semax synthesis include the desmethionine analog (deletion of Met at position 1), the Phe(D) epimer (racemization at the phenylalanine residue, which may produce an agonist-to-antagonist activity switch), and the methionine-sulfoxide form (Met(O)-MEHFPGP, produced by aerial oxidation during synthesis or storage). ^[4] The methionine-sulfoxide form typically elutes slightly earlier than the native sequence under standard gradient conditions and can be detected as a shoulder on the main HPLC peak if present at more than 1-2% abundance.

Independent Verification

For research groups requiring the highest confidence in compound identity, independent third-party verification is recommended. Options include:

Sending an aliquot (typically 0.1-0.5 mg) to a peptide analytical service (several academic core facilities and commercial CROs offer this) for an independent HPLC/MS analysis. This costs $50-200 per sample and provides an unambiguous confirmation of the vendor's CoA data.

LC-MS/MS analysis of the reconstituted peptide solution in the researcher's own laboratory, if mass spectrometry infrastructure is available. The expected parent ion masses for Semax are: [M+H]+ = 814.4 Da; [M+2H]2+ = 407.7 Da. Product ion fragmentation should yield the expected b-ion and y-ion series consistent with the MEHFPGP sequence.

For studies involving gene expression or neurotrophin endpoints, a positive control (known BDNF-stimulating agent, such as K-252a or 4-aminopyridine at appropriate concentrations for the cell model) in the same experiment provides assurance that the assay system is functional and responsive, independent of Semax identity.

See the comprehensive guidance at our supplier evaluation guide for how to evaluate vendor documentation systematically, and our CoA reading guide for interpreting analytical data.

Dosage and Reconstitution

Literature-Reported Research Doses

The rodent literature on Semax concentrates research doses in the range of 50-100 mcg/kg body weight for in vivo studies, administered intranasally or subcutaneously. ^[6][11][12] A 250 g Wistar rat at 50 mcg/kg would receive 12.5 mcg total per administration, while a 300 g Sprague-Dawley at 100 mcg/kg would receive 30 mcg. These are very small masses relative to the 5 mg vial content, underscoring the importance of accurate dilution and volumetric precision in research protocol execution.

For in vitro cell culture experiments, published literature has used concentrations from 0.1 to 10 micromolar in primary neuron culture and cell line systems. ^[5] At a molecular weight of 813.93 g/mol, a 1 micromolar solution requires 0.814 mcg/mL. A working stock of 100 micromolar (81.4 mcg/mL) reconstituted in PBS can be diluted to experimental concentrations from a single stock solution.

Reconstitution Protocol (Research Context)

For detailed procedural guidance, see our peptide reconstitution guide and dosage calculation guide. The following summarizes key parameters for Semax specifically.

Worked example 1 (standard in vivo rodent stock, 500 mcg/mL): A 5 mg vial reconstituted with 10 mL of bacteriostatic water yields 500 mcg/mL (0.5 mg/mL). For a 250 g rat at 50 mcg/kg (12.5 mcg total dose), the injection volume is 25 microliters. For intranasal administration in rodents, this volume is typically delivered as 12.5 microliters per nostril using a blunted pipette tip or micropipette.

Worked example 2 (lower-concentration stock for smaller doses): If the research protocol calls for 10 mcg/kg in 30 g mice, the dose per animal is 0.3 mcg. From a 500 mcg/mL stock, the required volume is 0.6 microliters, which is below the practical handling limit for most pipettes. A 1:10 dilution of the stock to 50 mcg/mL allows delivery of 6 microliters per animal, a more manageable injection volume. This diluted working solution should be prepared fresh from the stock on each experimental day.

Worked example 3 (in vitro micromolar concentration series): For a dose-response experiment testing 0.1, 1, 3, and 10 micromolar concentrations in primary neuron culture (2 mL per well), prepare a 1 millimolar (814 mcg/mL) stock in sterile PBS, sterile-filter through a 0.22-micrometer membrane, and aliquot for single-use storage at -80°C. Dilute fresh for each experiment: 10 microliters of 1 mM stock into 990 microliters of culture medium = 10 micromolar; further dilutions yield lower concentrations.

Stability and Storage Considerations

Lyophilized Semax is stable at -20°C for at least 24 months when kept desiccated and protected from light. The primary degradation pathways for the dry powder are oxidation of the methionine residue (requiring oxygen and moisture) and non-enzymatic racemization (requiring elevated temperature). Standard -20°C storage with silica gel desiccant in the vial packaging reliably suppresses both pathways.

Reconstituted Semax in bacteriostatic water can be stored at 4°C for up to 28 days with acceptable stability, though some degradation will accumulate over this period. For long-term storage of reconstituted material, aliquoting into single-use volumes and storing at -80°C is recommended. Avoid repeated freeze-thaw cycles; each cycle introduces mechanical stress that can promote aggregation of the peptide at interface surfaces.

Side Effects and Safety Profile

Preclinical Safety Observations

In rodent studies, Semax at literature-reported research doses (50-100 mcg/kg) has not produced overt toxicity signals. Acute toxicity studies reported in the Russian literature suggest an LD50 substantially above pharmacologically active doses, placing the therapeutic index in the favorable range seen with many peptide compounds. ^[15] Standard hematological and biochemical panels in chronic administration studies (up to 30 days in rats) have not shown hepatotoxic, nephrotoxic, or hematological abnormalities at doses up to 10-fold above the typical research dose range.

ACTH-related compounds carry a theoretical risk of HPA axis modulation, which was the primary concern motivating the design of Semax as an ACTH fragment lacking corticotropic activity. Experimental data confirm that Semax does not stimulate cortisol/corticosterone release in rodent or human studies at pharmacologically relevant doses. ^[15] This is attributed to the absence of the ACTH(1-3) sequence (His-Phe-Arg) required for MC2R engagement, which is the adrenocortical receptor mediating cortisol secretion.

Behavioral toxicity in the sense of adverse effects on anxiety, locomotion, or pain sensitivity has been specifically examined in some studies and not observed at standard research doses. The inverted-U dose-response for cognitive endpoints (discussed in the Koplik et al. study above) suggests that suprapharmacological doses may impair rather than enhance performance, which is a common feature of catecholaminergic modulator compounds and is a reason to avoid dose escalation beyond established research ranges in model systems.

Immune and Inflammatory Considerations

The Pro-Gly-Pro metabolite of Semax has chemotactic activity for neutrophils and may influence local immune cell recruitment at sites of administration. This is unlikely to be relevant for systemic research protocols but could be a confounding variable in experiments involving intranasal administration and measurements of neuroinflammatory markers. Researchers studying cytokine profiles or microglial activation as endpoints should consider appropriate vehicle controls that account for any PGP-mediated effects. ^[14]

Russian Clinical Literature Safety Data

The Russian clinical literature reports use of Semax intranasal drops (0.1% solution, 2-3 drops per nostril) in stroke patients and individuals with cognitive impairment. Reported adverse events in these studies have been limited to local nasal irritation at the application site and, in a small proportion of patients, mild headache. No serious adverse events attributed to Semax were reported in the published Russian clinical trials reviewed. ^[16]

These clinical data should be interpreted with substantial caution. The trials were conducted without the trial design standards (randomization, blinding, independent data monitoring) expected by regulatory agencies in the US, EU, and UK, and publication bias in the Russian pharmacological literature during the 1990s-2000s was documented as a concern. The safety database for Semax in Western clinical research contexts is effectively zero.

How Semax Compares to Related Research Peptides

Semax versus Selank

Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is the closest structural relative to Semax in current research use: it shares the C-terminal Pro-Gly-Pro extension and was developed by the same Russian research group. ^[9] Both compounds upregulate BDNF and share some behavioral effects, but their primary pharmacological profiles diverge substantially. Selank acts primarily through GABA-A receptor modulation and serotonergic pathways, producing anxiolytic-like effects as its most consistent behavioral outcome. Semax, by contrast, shows stronger effects on attentional and mnemonic endpoints with less evidence for anxiolytic action.

Researchers choosing between the two for cognitive enhancement models will generally prefer Semax for attention, working memory, and learning-acquisition endpoints. For anxiety-comorbid cognitive deficit models, Selank may be more appropriate. The two compounds are sometimes studied in combination in the Russian literature, though the rationale for combination use has not been rigorously mechanistically justified.

Semax versus Dihexa

Dihexa (PNB-0408) has attracted interest because of preclinical data suggesting synaptogenic activity through HGF/c-Met signaling that is substantially more potent on a molar basis than BDNF. ^[17] However, the evidence base for Dihexa is concentrated in the laboratory of a single research group (Wright et al., Washington State University), and independent replication has been limited. Semax has a broader and more geographically distributed literature, and while quality concerns exist for the Russian clinical data, the mechanistic studies in cell culture and rodent models are more numerous and come from multiple independent groups.

Researchers with a strong interest in synaptogenesis specifically may find Dihexa worth investigating in parallel, but those seeking the best-documented BDNF-pathway compound in the research peptide space will find Semax the stronger choice given current literature.

Semax versus Cerebrolysin

Cerebrolysin is a pig brain-derived peptide mixture that has been studied in controlled clinical trials for Alzheimer's disease and post-stroke cognitive impairment, with some positive findings. ^[18] Its evidence base is substantially stronger than Semax's from a clinical rigor standpoint, but it is an IV-only formulation, not available as a lyophilized research vial, and its heterogeneous composition makes mechanistic research interpretation difficult. Semax is the more tractable research tool for investigators interested in well-defined molecular mechanisms; Cerebrolysin is more relevant for translational clinical researchers.

Open Research Questions

Several important questions about Semax remain unresolved in the published literature, and researchers entering this space should be aware of them.

Receptor identity and specificity. Despite widespread assumption of MC4R as the primary target, direct binding studies with high-affinity radioligands at sufficient resolution to confidently assign Semax's CNS effects to MC4R have not been published in English-language peer-reviewed journals. Some observations are inconsistent with simple MC4R agonism, including the relatively modest in vitro binding affinity and some behavioral effects that persist after pharmacological MC4R blockade in rodents. Alternative targets including NMDA receptor modulators (potentially via the PGP metabolite) and direct neurotrophin receptor interactions have been proposed but not systematically investigated.

Dose-response characterization in modern behavioral paradigms. The majority of the cognitive behavioral data come from studies conducted in the 1990s-2000s using paradigms and analytical standards that predate current best practices. Modern touchscreen-based operant paradigms (which enable more precise quantification of cognitive subdomains and have validated translational relationships to human neuropsychological measures) have not been used to characterize Semax, to the best of our knowledge. This is a genuine research gap.

Sex differences. Almost all published rodent studies have used male animals exclusively. Given the well-documented sex differences in BDNF expression, melanocortin receptor function, and hippocampal plasticity, it is unclear whether Semax effects generalize equally to female subjects. No sex-comparative data are available.

Interaction with pathological states. Whether Semax effects on BDNF and cognition are amplified, attenuated, or qualitatively altered in disease models (Alzheimer's pathology, traumatic brain injury, depression) beyond stroke and acute stress models has not been comprehensively examined.

Pharmacological Context: Melanocortin System and Neuroplasticity

To situate Semax within broader neuroscience, it is worth reviewing the pharmacological context of the melanocortin system in brain function. The melanocortin peptides (alpha-MSH, beta-MSH, gamma-MSH, ACTH, and their derivatives) are produced from the proopiomelanocortin (POMC) precursor and regulate a diverse set of physiological functions through five receptor subtypes (MC1R-MC5R). ^[3]

In the brain, MC4R is the dominant subtype and is expressed most heavily in the hypothalamus, cortex, hippocampus, and brainstem. Its functions include regulation of energy balance (through leptin-melanocortin interactions in the hypothalamus), sexual behavior, and cognitive functions. The hypothalamic roles of MC4R have been extensively characterized in the context of obesity research; the cognitive roles have received less attention but are becoming clearer as conditional knockout and pharmacological tools have improved. ^[3]

BDNF occupies a central position in synaptic plasticity biology. As the most abundant neurotrophin in the adult brain, it promotes the survival of existing neurons, encourages the growth and differentiation of new neurons and synapses, and supports both LTP (the cellular correlate of memory formation) and LTD (long-term depression, important for memory erasure and updating). The convergence of melanocortin signaling on BDNF transcription creates a pharmacologically important link: compounds that activate MC4R may broadly enhance plasticity by upregulating the neurotrophin most critical for adult synaptic remodeling. ^[5]

The Pro-Gly-Pro metabolite dimension adds another layer of context. PGP is a cleavage product of the collagen alpha-1 chain and serves as a neutrophil chemoattractant during tissue injury and repair. In the CNS, neuroinflammation is increasingly recognized as a modulator of synaptic plasticity and a contributor to multiple psychiatric and neurodegenerative conditions. The possibility that Semax's metabolite contributes to anti-inflammatory regulation in injured neural tissue may explain some of the neuroprotection data that are difficult to account for through MC4R and BDNF mechanisms alone. ^[14]

The interaction between the melanocortin system and the HPA axis deserves explicit discussion. The observation that Semax lacks corticotropic activity despite being derived from ACTH is not surprising from a structural standpoint but is clinically and experimentally important. The Mc2R (the adrenocortical ACTH receptor) requires the ACTH(1-3) sequence for recognition, and Semax, beginning at position 4 of ACTH, lacks this epitope entirely. ^[15] Researchers can therefore study Semax's effects on neuroplasticity and cognition without the confounding variable of stress-axis activation, which would be an unavoidable complication with full ACTH or alpha-MSH.

Where to Buy Semax 5mg

For research procurement, Apollo Peptide Sciences is the vendor for this listing. Apollo provides Semax 5mg at $30.00 per vial with HPLC purity certificates and mass spectrometry confirmation available on request. The lot-specific CoA can be verified by the buyer before order placement, which is the minimum standard we recommend for any in vivo research application.

When evaluating vendors for any research peptide purchase, the criteria that matter most are: (1) HPLC trace showing the purity claim with visible impurity peaks integrated, (2) mass spectrometry confirmation of molecular identity, (3) documented endotoxin testing with results below 1 EU/mg, and (4) clear lot-to-lot consistency. Apollo Peptide Sciences meets these criteria for their Semax product based on our review of available documentation.

For a broader discussion of how to evaluate peptide suppliers, including what CoA red flags look like and how to use third-party testing services, see our supplier comparison guide. If you are comparing Apollo's Semax against other vendor options, our independent Semax product review page brings together the specification data, CoA documentation summary, and sourcing notes in a single reference.

Researchers who need complementary compounds for their cognitive research protocols may also want to review our coverage of Selank (for the anxiolytic-BDNF side of the same research question) and BPC-157 (for neuroprotection and angiogenesis endpoints in CNS injury models).

FAQ